Seattle vaccine developer raises $18M in Series A

Seattle-based Immune Design has raised an impressive $18 million in its first round of venture capital. The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies. The company only has three full time staffers, but Immune Design says it will quickly expand to 30. And the developer has already attracted some top venture capital groups. Alta Partners, The Column Group and Versant Ventures all participated in the round.

- check out the company's release
- read the story from the Seattle Post-Intelligencer

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.